CareDx (CDNA) Q4 2025 earnings review
Accelerating Volumes and Clarified Regulatory Risks Signal a Turning Point
CareDx finished 2025 with accelerating momentum, breaking out of a year plagued by regulatory anxiety. Q4 revenue jumped 25% YoY to $108.4M, driven by a 17% surge in core testing volumes and a massive 47% leap in Digital Solutions. More importantly, management finally quantified the dreaded Medicare LCD overhang—which previously sparked fears of a $15M to $30M hit—at just $7.5M for the first half of 2026. This is a highly manageable figure that allows them to guide for stable ~14% revenue growth next year. While a sudden $7M cash compensation expense artificially compressed Q4's Adjusted EBITDA, the underlying cash generation and volume trends point to a company successfully outgrowing its headwinds.
🐂 Bull Case
The Medicare LCD, which has been the primary bear thesis for multiple quarters, is now officially quantified at a $7.5M impact for 2026. This allows investors to finally model the future without worst-case scenario assumptions.
Testing volume growth has accelerated for four consecutive quarters (12% -> 13% -> 13% -> 17%), proving that the re-adoption of surveillance protocols at transplant centers is durable and expanding.
🐻 Bear Case
While Adjusted EBITDA was positive ($7M), it was artificially suppressed by a $7M cash payment in lieu of equity for non-executives, while underlying ASPs continue to be propped up by prior-period collections.
The shift from equity grants to cash compensation for non-executives directly impacts operating cash flow. If this becomes a recurring strategy, it will weigh heavily on free cash flow generation.
⚖️ Verdict: 🟢
Bullish. The 25% revenue growth and 17% volume growth demonstrate excellent commercial execution. With the Medicare LCD risk now quantified and absorbed into healthy 2026 guidance, the fundamental growth story is back in focus.
Key Themes
Core Testing Volumes Accelerating
Testing services volume reached 53,000 in Q4, driving a 17% YoY growth rate. This marks an acceleration from the 12-13% growth seen in the first three quarters of the year. The sustained expansion confirms that CareDx's 'solution selling' and the re-establishment of clinical surveillance protocols are successfully countering earlier market softness.
Digital Solutions Breakout
Patient and Digital Solutions is transitioning from an ancillary segment to a material growth driver. Revenue exploded 47% YoY in Q4 to $16.8M, accelerating from 30% growth in Q3. This validates management's strategy of embedding CareDx software into hospital IT infrastructures, creating sticky ecosystems that subsequently pull through testing volumes.
Workflow Integration via Epic Aura
CareDx advanced its Epic Aura EMR integrations, with 7 transplant centers now live and approximately 20 implementations underway. In prior quarters, pilots demonstrated a 20% reduction in order turnaround times and a 60% drop in specimen holds. Rolling this out aggressively in 2026 will heavily reduce ordering friction and defend market share.
Core ASP Remains Obscured by One-Offs
In Q4, average revenue per test was reported at ~$1,480. However, this includes ~$5M in prior period collections. This contradicts the narrative of a cleanly improving revenue cycle. This exact issue occurred in Q3 ($5.9M benefit) and Q2 ($3.8M write-off). The reliance on out-of-period RCM catches masks the true underlying Average Selling Price (ASP) for current operations, creating modeling risk.
Earnings Quality: The Compensation Shift
Adjusted EBITDA in Q4 fell to $7M from $10M a year ago. Management notes this includes ~$7M of operating expenses for 'compensation in lieu of equity grants for non-executives.' Shifting compensation from equity (historically added back to non-GAAP metrics) to cash directly hits the bottom line and operating cash flow. It is critical to monitor if this is a one-time adjustment or a structural change in compensation philosophy.
Medicare LCD Impact Quantified (Macro/Regulatory)
After modeling $15M to $30M annual headwinds in Q2 regarding the draft Medicare Local Coverage Determination (LCD), management provided concrete parameters. The 2026 guidance includes an estimated 6-month impact of ~$7.5M. While still a headwind, the clarity removes the tail-risk uncertainty that has plagued the stock for months.
Next-Gen Innovation: ImmuneScape & 10x Genomics
CareDx launched ImmuneScape via a collaboration with 10x Genomics to create a multiomics discovery platform. Alongside pivotal validation data for AlloHeme (expanding beyond solid organs into cell therapy and hematologic malignancies), the company is visibly diversifying its product pipeline to ensure long-term relevance beyond current cfDNA assays.
Other KPIs
Accelerating. Grew 23% YoY, up from 19% growth in Q3 and 15% in Q1. This represents 72% of total Q4 revenue and remains the undeniable core engine of the business.
Reversing positively. The company generated solid operating cash flow for the year, a stark turnaround from historical cash burns. Q4 alone generated $21.4M. This strong cash generation allowed the company to comfortably repurchase $88M in stock throughout the year while maintaining $201M in liquidity.
Guidance
Stable. The midpoint of $432M implies 13.7% YoY growth, virtually identical to the 14% growth delivered in FY25. This is highly encouraging considering the guidance bakes in a $7.5M regulatory headwind from the Medicare LCD policy.
Accelerating. The midpoint of $37.5M implies a 17% increase over FY25's $32M result. The wide range likely reflects ongoing variables in Average Selling Price collections, RCM efficiency gains, and exactly how the LCD policy alters test utilization in the second half of 2026.
Key Questions
Compensation Structure Shift
You recorded a $7M operating expense in Q4 for 'compensation in lieu of equity grants.' Is this a one-time adjustment, or a structural change in how you compensate non-executives moving forward? How does this impact your targeted 20% Adjusted EBITDA margins for 2027?
Underlying Core ASP
For three consecutive quarters, testing revenue has been heavily influenced by prior period collections ($5M in Q4, $5.9M in Q3). When do you expect these historical clean-ups to normalize so we can view the true, underlying ASP generated by your new RCM processes?
Medicare LCD Implementation Mechanics
You've guided to a $7.5M impact for the Medicare LCD over 6 months. Can you break down whether this impact is driven primarily by reduced testing frequency/volumes, or by a reduction in reimbursement rates per test?
Epic Aura Volume Uplift
With 7 Epic Aura integrations live and 20 underway, are you seeing the historical '10% volume uplift' post-implementation hold true across these new centers, and what percentage of your total volume do you expect to run through Epic by the end of 2026?